Drug Shortage Report for TEVA-SPIRONOLACTONE
| Report ID | 128339 |
| Drug Identification Number | 00613215 |
| Brand name | TEVA-SPIRONOLACTONE |
| Common or Proper name | SPIRONOLACTONE 25MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | SPIRONOLACTONE |
| Strength(s) | 25MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 500 |
| ATC code | C03DA |
| ATC description | POTASSIUM-SPARING AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-11-11 |
| Estimated end date | 2021-01-31 |
| Actual end date | 2021-01-27 |
| Shortage status | Resolved |
| Updated date | 2021-01-28 |
| Company comments | |
| Health Canada comments | |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.